LIVIVO - Search results -

Search results

Result 1 - 10 of total 112

Search options

Article: Real-world analysis of the use of lenvatinib in differentiated thyroid cancers.

Peelay, Zoya / Parekh, Deevyashali / Patil, Vijay M / Noronha, Vanita / Menon, Nandini / Prabhash, Kumar

Ecancermedicalscience

2023 Volume 17, Page(s) 1500

Abstract: Introduction: Lenvatinib is one of the approved treatments for radioiodine-refractory differentiated thyroid cancers. However, there is very limited data from India on real-world efficacy and adverse events of Lenvatinib and hence this analysis was ... ...

Abstract	Introduction: Lenvatinib is one of the approved treatments for radioiodine-refractory differentiated thyroid cancers. However, there is very limited data from India on real-world efficacy and adverse events of Lenvatinib and hence this analysis was performed. Methods: This was a retrospective analysis in which patients of radioiodine-refractory differentiated thyroid cancer as per the SELECT study criteria, who received lenvatinib, were selected for the study over the last 4 years. The baseline demographic characteristics, adverse events of lenvatinib, the date of progression and the date of overall survival (OS) were extracted from the electronic medical records of Tata Memorial Hospital. SPSS version 20 was used for analysis. Results: The median starting dose of lenvatinib was 20 mg. Fifteen events for progression had occurred and the median progression-free survival (PFS) was 12.2 months [95% CI: 4.4-not available (NA)]. The events for OS analysis were 12. The median OS was 35.3 months (95% CI: 11.4-NA). There was no impact on starting dose on PFS or OS. Conclusion: The real-world data of Lenvatinib suggest a lot of variability in the starting dose. In spite of this variability, the response rates and OS are similar to that noted in pivotal study. This suggests a case for need for more studies evaluating lower doses of Lenvatinib.
Language	English
Publishing date	2023-01-30
Publishing country	England
Document type	Journal Article
ISSN	1754-6605
ISSN	1754-6605
DOI	10.3332/ecancer.2023.1500
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: A Survey of Satisfaction with Treatment among Brain Tumor Patients.

Singh, Gunjesh Kumar / Alone, Mitali / Menon, Nandini / Dale, Ochin / Bhelekar, Arti / Patil, Vijay M

South Asian journal of cancer

2021 Volume 9, Issue 4, Page(s) 262

Language	English
Publishing date	2021-06-12
Publishing country	India
Document type	Journal Article
ZDB-ID	2719571-5
ISSN	2278-4306 ; 2278-330X
ISSN (online)	2278-4306
ISSN	2278-330X
DOI	10.1055/s-0041-1729494
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Neoadjuvant chemotherapy in a rare type of very locally advanced sinonasal carcinomas - long-term results from a tertiary care centre.

Saha, Saswata / Patil, Vijay M / Noronha, Vanita / Menon, Nandini / Singh, Ajay Kumar / Suman, Mannavi / Agrawal, Amit / Khaddar, Satvik / Chakraborty, Shatabdi / Pai, Prathamesh S / Chaukar, Devendra A / Chaturvedi, Pankaj / Laskar, Sarbani Ghosh / Prabhash, Kumar

Ecancermedicalscience

2023 Volume 17, Page(s) 1549

Abstract: Introduction: Sinonasal carcinomas are a rare type of head and neck malignancy with various histologies. The outcomes of patients with unresectable locally advanced sinonasal carcinomas are poor. Hence, we performed this analysis to study the long-term ... ...

Abstract	Introduction: Sinonasal carcinomas are a rare type of head and neck malignancy with various histologies. The outcomes of patients with unresectable locally advanced sinonasal carcinomas are poor. Hence, we performed this analysis to study the long-term outcomes of sinonasal adenocarcinoma (SNAC) and sinonasal undifferentiated carcinomas (SNUC) where neoadjuvant chemotherapy (NACT) has been given followed by local therapy. Methods: 16 patients with SNUC and adenocarcinoma who received NACT were found eligible for the study. Descriptive statistical analysis was performed for baseline characteristics, adverse events and treatment compliance. Kaplan Meir methods were used for the estimation of progression-free survival (PFS) and overall survival (OS). Results: Seven (43.75%) adenocarcinoma and nine (56.25%) SNUC patients were identified. The median age of the whole cohort was 48.5 years. The median number of cycles delivered was 3 (IQR 1-8). The incidence of grade 3-4 toxicity (CTCAE version 5.0) was 18.75%. The response was partial response or better in seven patients (43.75%). Post-NACT 11 patients ( Conclusion: The study shows a favourable role of NACT in improving resectability, significant improvement in PFS and non-significant improvement in OS after surgery.
Language	English
Publishing date	2023-05-11
Publishing country	England
Document type	Case Reports
ISSN	1754-6605
ISSN	1754-6605
DOI	10.3332/ecancer.2023.1549
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Reply to T. Tanaka et al and F. Liang.

Noronha, Vanita / Patil, Vijay M / Joshi, Amit / Menon, Nandini / Chougule, Anuradha / Prabhash, Kumar

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2020 Volume 38, Issue 8, Page(s) 844–846

MeSH term(s)	Carboplatin ; ErbB Receptors ; Gefitinib ; Humans ; Lung Neoplasms ; Pemetrexed
Chemical Substances	Pemetrexed (04Q9AIZ7NO) ; Carboplatin (BG3F62OND5) ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Gefitinib (S65743JHBS)
Language	English
Publishing date	2020-01-02
Publishing country	United States
Document type	Letter ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.19.02974
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic.

Bhattacharjee, Atanu / Patil, Vijay M / Dikshit, Rajesh / Prabhash, Kumar / Singh, Arjun / Chaturvedi, Pankaj

Head & neck

2020 Volume 42, Issue 6, Page(s) 1173–1178

Abstract: Background: The coronavirus infection is rapidly spreading, putting a strain on health care services across the globe. Patients with oral cancer are susceptible often immunosuppressed due to the disease and/or the treatment received.: Methods: We ... ...

Abstract	Background: The coronavirus infection is rapidly spreading, putting a strain on health care services across the globe. Patients with oral cancer are susceptible often immunosuppressed due to the disease and/or the treatment received. Methods: We performed a simulation of the currently available data using a multistate and hazards model to provide an objective model for counseling and decision making for health care workers. Results: Stage IV patients with oral cancer who did not receive treatment had progression of disease and an increased mortality rate compared to patients who receive treatment but did not contract COVID-19. The patients who received treatment and got affected with COVID-19 had a far worse impact and higher mortality rate than all other groups. Conclusion: Isolation and deferring treatment for stage IV patients with oral cancer, so as to avoid hospital visits and contraction of COVID-19, is an advisable strategy based on this model.
MeSH term(s)	COVID-19 ; Cause of Death ; Clinical Decision-Making/methods ; Computer Simulation ; Coronavirus Infections/epidemiology ; Coronavirus Infections/prevention & control ; Disease Management ; Disease-Free Survival ; Female ; Humans ; Male ; Mouth Neoplasms/mortality ; Mouth Neoplasms/pathology ; Mouth Neoplasms/surgery ; Neoplasm Invasiveness/pathology ; Neoplasm Staging ; Pandemics/prevention & control ; Patient Selection ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/prevention & control ; Proportional Hazards Models ; Risk Assessment ; Survival Analysis ; United States
Keywords	covid19
Language	English
Publishing date	2020-04-28
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Multicenter Study
ZDB-ID	645165-2
ISSN	1097-0347 ; 0148-6403 ; 1043-3074
ISSN (online)	1097-0347
ISSN	0148-6403 ; 1043-3074
DOI	10.1002/hed.26196
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1493: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Real world data on long term outcome of neoadjuvant chemotherapy in locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation - Results from a single centre study.

Saha, Saswata / Patil, Vijay M / Noronha, Vanita / Menon, Nandini / Kumar Singh, Ajay / Patlekar, Gargi / Yadav, Nishant / Pai, Prathamesh S / Chaukar, Devendra A / Chaturvedi, Pankaj / Ghosh Laskar, Sarbani / Prabhash, Kumar

Oral oncology

2023 Volume 144, Page(s) 106486

Abstract: Introduction: Esthesioneuroblastoma and sinonasal neuroendocrine carcinoma (SNEC) are the most common histological subtypes of non-squamous Sinonasal Tumors. A multidisciplinary approach is preferred for locally advanced unresectable ... ...

Abstract	Introduction: Esthesioneuroblastoma and sinonasal neuroendocrine carcinoma (SNEC) are the most common histological subtypes of non-squamous Sinonasal Tumors. A multidisciplinary approach is preferred for locally advanced unresectable esthesioneuroblastoma and SNEC. Methods: From June 2010 to October 2021, 59 patients with esthesioneuroblastoma and SNEC received NACT. NACT consists of 2-3 cycles of Etoposide-Platinum based chemotherapy. Depending upon response and performance status, subsequent therapy was planned. SPSS descriptive statistics were performed for analysis. Kaplan Meir methods were used for the estimation of Progression Free Survival (PFS) and Overall Survival (OS). Results: 45 (76.3 %) Esthesioneuroblastoma and 14 (23.7 %) SNEC patients received NACT. The median age of the population was 45 years (range 20-81 years). The majority of patients received 2-3 cycles of Platinum (Cisplatin or Carboplatin) + Etoposide as NACT. 28 patients (47.5%) underwent surgery and 20 patients (33.9%) received definitive chemoradiotherapy after NACT. The most common grade 3 or above adverse events were anemia (13.6%), neutropenia (27.1), and hyponatremia (45.8%). At the time of analysis, the median PFS was 56 months (95% CI 31 months to 77 months), and the median OS was 70 months (95% CI 56 months to 86 months). The most common late toxicities noticed were metabolic syndrome (42.4%), hyperglycemia (39%), nasal bleeding (33.9%), hypertension (17%), dyslipidemia (8.5%), and hypothyroidism (5.1%). Conclusion: The study shows that NACT is safe, and can be easily delivered without any life-threatening toxicities, with a favorable response and improved survival in this subset of patients.
MeSH term(s)	Humans ; Young Adult ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Neoadjuvant Therapy/methods ; Esthesioneuroblastoma, Olfactory/drug therapy ; Etoposide/therapeutic use ; Retrospective Studies ; Cisplatin ; Carcinoma, Neuroendocrine/drug therapy ; Paranasal Sinus Neoplasms/pathology ; Nasal Cavity/pathology ; Nose Neoplasms/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical Substances	Etoposide (6PLQ3CP4P3) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2023-07-04
Publishing country	England
Document type	Letter
ZDB-ID	1120465-5
ISSN	1879-0593 ; 0964-1955 ; 1368-8375
ISSN (online)	1879-0593
ISSN	0964-1955 ; 1368-8375
DOI	10.1016/j.oraloncology.2023.106486
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4869: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings.

Kapoor, Akhil / Noronha, Vanita / Patil, Vijay M / Menon, Nandini / Joshi, Amit / Abraham, George / Prabhash, Kumar

Medicine

2021 Volume 100, Issue 13, Page(s) e25115

Abstract: Abstract: Immune checkpoint inhibitors (ICIs) are rapidly being incorporated as treatment option either alone or in combination with chemotherapy in most of the solid tumors. Since there is very limited data of ICI in patients with poor performance ... ...

Abstract	Abstract: Immune checkpoint inhibitors (ICIs) are rapidly being incorporated as treatment option either alone or in combination with chemotherapy in most of the solid tumors. Since there is very limited data of ICI in patients with poor performance status (PS) from the real world settings, we performed a retrospective audit of patients who received ICI and report the analysis based on ECOG PS of these patients.This study is a retrospective audit of a prospectively collected database of patients receiving ICIs for advanced solid tumors in any line between August 2015 and November 2018 at Tata Memorial Hospital, Mumbai, India. All statistical calculations were performed using SPSS statistical software for windows version 20.0.A total of 155 patients who received ICIs during the specified period were evaluated for this study. Baseline ECOG PS 0-1 (n = 103, 66.4%) patients was associated with median OS 9.1 (95% CI [confidence interval], 4.4-NR) months when compared to ECOG 2-4 (n = 52, 33.5%) which had a median OS of 2.9 (95% CI; 1.8-5.5) months (HR, 1.7, 95% CI, 1.1-2.7, log rank P = .017). The disease control rate for the poor PS group was 34.6%. However, 27.3% patients (95% CI: 20.3-34.3) were still alive at 1 year. Median OS in patients with PS 2 was 3.7 months (95% CI: 0-11.6) as compared to 1.8 months (95% CI: 0.2-3.4) for those with PS 3-4 (HR-2.0; 95% CI: 1.0-3.9, P = .041). The tolerance to ICIs was good with no grade 3/4 toxicities in 44 (84.6%) patients.Immune checkpoint inhibitors are a safe and effective therapeutic option even in solid tumor patients with poor performance status.
MeSH term(s)	Antineoplastic Agents, Immunological/therapeutic use ; Databases, Factual ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Kaplan-Meier Estimate ; Male ; Medical Audit ; Medical Oncology/statistics & numerical data ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/mortality ; Outcome Assessment, Health Care ; Prospective Studies ; Retrospective Studies ; Treatment Outcome
Chemical Substances	Antineoplastic Agents, Immunological ; Immune Checkpoint Inhibitors
Language	English
Publishing date	2021-03-26
Publishing country	United States
Document type	Journal Article
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000025115
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis.

Noronha, Vanita / Patil, Vijay M / Singh, Gunjesh Kumar / Joshi, Amit / Menon, Nandini / Lashkar, Sarbani Ghosh / Mathrudev, Vijayalakshmi / Satam, Kavita Nawale / Prabhash, Kumar

Journal of the Egyptian National Cancer Institute

2021 Volume 33, Issue 1, Page(s) 12

Abstract: Background: Acute oral mucositis has been infrequently studied in the patients with head and neck squamous cell carcinoma (HNSCC) receiving once-weekly cisplatin-based chemoradiotherapy (CRT). Hence, this analysis was conducted to explore the various ... ...

Abstract	Background: Acute oral mucositis has been infrequently studied in the patients with head and neck squamous cell carcinoma (HNSCC) receiving once-weekly cisplatin-based chemoradiotherapy (CRT). Hence, this analysis was conducted to explore the various aspects of the same. Results: The overall incidence of mucositis was 96.9% (n = 508) and of grade 3-5 mucositis was 61.3% (n = 321). The overall incidence of oral mucositis was similar in both the arms (CCRT and NCRT) (p value = 0.58) while grade 3-5 mucositis was more common in the NCRT arm (p value = 0.01). Out of all factors listed, the presence of nimotuzumab was the only significant risk factor for the development of grade 3 or more oral mucositis (p value = 0.01); (OR = 1.64, 95%CI 1.15-2.32). Delays in the treatment delivery were similar in both the arms. Conclusion: Acute oral mucositis is a common occurrence in locally advanced-HNSCC patients receiving chemoradiotherapy. Nimotuzumab is a significant factor for development of grade 3 and above oral mucositis.
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Chemoradiotherapy/adverse effects ; Cisplatin/adverse effects ; Head and Neck Neoplasms/therapy ; Humans ; Stomatitis/chemically induced ; Stomatitis/epidemiology
Chemical Substances	Antibodies, Monoclonal, Humanized ; nimotuzumab (6NS400BXKH) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2021-05-22
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	1176790-x
ISSN	2589-0409 ; 1110-0362
ISSN (online)	2589-0409
ISSN	1110-0362
DOI	10.1186/s43046-021-00069-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3918: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Weight loss and its impact on outcome in head and cancer patients during chemo-radiation.

Singh, Gunjesh Kumar / Patil, Vijay M / Noronha, Vanita / Joshi, Amit / Menon, Nandini / Lashkar, Sarbani Ghosh / Mathrudev, Vijayalakshmi / Satam, Kavita Nawale / Prabhash, Kumar

Oral oncology

2021 Volume 122, Page(s) 105522

Abstract: Background: Weight loss during chemotherapy and its impact on the cancer outcomes have been invariably reported in the literature. We also did a post-hoc analysis of a randomized phase III trial to see the same.: Materials and methods: The database ... ...

Abstract	Background: Weight loss during chemotherapy and its impact on the cancer outcomes have been invariably reported in the literature. We also did a post-hoc analysis of a randomized phase III trial to see the same. Materials and methods: The database of a recently published randomized study comparing cisplatin-radiation with nimotuzumab cisplatin-radiation was used for this analysis. Week-wise weight loss during the course of treatment was noted. The impact of severe weight loss (grade 2-3) on progression-free survival (PFS), locoregional control (LRC) and overall survival (OS) was studied using the Kaplan Meier method. Binary logistic regression analysis was used to see the effect of various factors. Results: Out of a total of 536 patients, weight loss was captured in 524. Out of these 524 patients, any degree of weight loss was seen in 293 (55.91%) patients. Grade 1 weight loss was noted in 192 (36.6%) patients, grade 2 in 96 (18.3%) and grade 3 in 5 (1%) patients. The 2-year PFS was 53% and 57.1% in severe and non-severe weight loss groups respectively (p-value = 0.36). The 2-year LRC was 60% in patients with severe weight loss, while it was 63.5% in those with non-severe weight loss (p-value = 0.47). The 2-year OS was 59.3% versus 62.2% in severe and non-severe weight loss cohorts respectively (p-value = 0.21). None of the factors was found to be associated with severe weight loss. Conclusion: Severe weight loss was uncommon in our patients. Weight loss during treatment was not associated with poor survival outcomes.
MeSH term(s)	Antibodies, Monoclonal, Humanized/therapeutic use ; Chemoradiotherapy ; Cisplatin/therapeutic use ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/radiotherapy ; Humans ; Kaplan-Meier Estimate ; Treatment Outcome ; Weight Loss
Chemical Substances	Antibodies, Monoclonal, Humanized ; nimotuzumab (6NS400BXKH) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2021-09-24
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial
ZDB-ID	1120465-5
ISSN	1879-0593 ; 0964-1955 ; 1368-8375
ISSN (online)	1879-0593
ISSN	0964-1955 ; 1368-8375
DOI	10.1016/j.oraloncology.2021.105522
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4869: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience.

Talreja, Vikas T / Noronha, Vanita / Patil, Vijay M / Joshi, Amit / Prabhash, Kumar

South Asian journal of cancer

2019 Volume 9, Issue 1, Page(s) 67–68

Language	English
Publishing date	2019-12-27
Publishing country	India
Document type	Journal Article
ZDB-ID	2719571-5
ISSN	2278-4306 ; 2278-330X
ISSN (online)	2278-4306
ISSN	2278-330X
DOI	10.4103/sajc.sajc_364_19
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito